SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Seres Therapeutics Reports Third-Quarter 2026 Financial Results, Plans SER-155 Development

Seres Therapeutics reported third-quarter 2026 financial results and announced plans to advance development of SER-155 to prevent immune checkpoint inhibitor-related enterocolitis.

MCRB
SquawkNews Desk 1 updates Updated Nov 04, 2026, 12:12 PM UTC

Story updates

12:12:23 PM UTC
SquawkNews
Seres Therapeutics rutscht im dritten Quartal 2026 mit 16.29 Millionen US-Dollar in die Verlustzone;

Related stories

Peabody Energy Reports Third-Quarter Loss of $32.8 Million M impact | EQUITY | Nov 04, 2026, 12:49 PM UTC AtkinsRéalis Wins 10-Year Denver Airport Contract Worth Up to $135 Million The contract may authorize up to $135 million for Denver airport expansion over 10 years. M impact | EQUITY | Nov 04, 2026, 12:46 PM UTC Peabody Energy Q3 Revenue Reaches $1,096.3 Million Peabody Energy reported Q3 revenue of $1,096.3 million, versus the IBES estimate of $1,026 million. M impact | EQUITY | Nov 04, 2026, 12:45 PM UTC Saudi Cement Reports Higher Share of Associate’s Quarterly Net Profit Saudi Cement said its share of an associate’s net profit increased in the quarter. The amount and reporting period were not specified. M impact | EQUITY | Nov 04, 2026, 12:45 PM UTC Peabody Reports Quarterly Results Peabody reported results for the quarter ended September 30, 2026. M impact | EQUITY | Nov 04, 2026, 12:45 PM UTC Laan & Spar Bank Q3 Profit DKK 111.2 Million M impact | EQUITY | Nov 04, 2026, 12:45 PM UTC